Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (309)	11/18/1998 10:57:00 AM
From: Steven Yang	Read Replies (2) \| Respond to of 328

Miljenko (and other NXTR investors), The 10Q for 98Q3 has come out. We have the answer to the questions we had about where the cash from SKW deal has gone. AR increases slightly more than $2M from 98Q2 to 98Q3. Most of the $15M from the SKW deal goes to NXTR's share of the Progoli's working capital ($4.9M) and payment of debt (around 6-7M). I was concerned about the possibility of a huge AR increase. The 10Q removes this uncertainty. Steven ps: NXTR seems to get some attention of the street lately.